Vertex Pharmaceuticals
50 Northern Ave
Boston
Massachusetts
02210
United States
Tel: 617-341-6100
Website: http://www.vrtx.com/
740 articles with Vertex Pharmaceuticals
-
Vertex Pharmaceuticals Incorporated Hepatitis C Drug Effective In Small Study
1/9/2006
-
Vertex Pharmaceuticals Incorporated Announces Key Business Objectives For 2006 At 24th Annual JPMorgan Healthcare Conference
1/9/2006
-
Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At The 24th Annual JPMorgan Healthcare Conference
1/4/2006
-
GlaxoSmithKline And Vertex Pharmaceuticals Incorporated Announce Presentation Of Data Supporting Development Of Investigational HIV Protease Inhibitor Brecanavir
12/16/2005
-
GlaxoSmithKline And Vertex Pharmaceuticals Incorporated Announce New Collaboration To Develop And Commercialize VX-409, A Novel Compound For The Treatment Of Pain
12/13/2005
-
Vertex Pharmaceuticals Incorporated Expects $19.5 Million In Milestone Payments
12/8/2005
-
FDA Grants Fast Track Designation To Vertex Pharmaceuticals Incorporated's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
12/8/2005
-
Vertex Pharmaceuticals Incorporated Announces That VX-680 Demonstrates Effect On Clinically Relevant Biomarker In Phase I Cancer Study
12/7/2005
-
Vertex Pharmaceuticals Incorporated Announces Start Of Phase II Clinical Development For Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
12/5/2005
-
Vertex Pharmaceuticals Incorporated Announces Start Of Phase II Clinical Development For Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
12/5/2005
-
Vertex Pharmaceuticals Incorporated Announces Agreements To Exchange Common Stock For $95.0 Million Of Its Convertible Senior Subordinated Notes Due 2011
11/29/2005
-
Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At Credit Suisse First Boston's Health Care Conference
11/14/2005
-
Vertex Pharmaceuticals Incorporated Release: AASLD Presentations Support The Initiation Of A Broad Phase II Program With VX-950, An Investigational Oral HCV Protease Inhibitor
11/11/2005
-
Vertex Pharmaceuticals Incorporated Announces A Conference Call And Webcast To Review VX- 950 Presentations At The Upcoming AASLD Meeting
11/9/2005
-
Vertex Pharmaceuticals Incorporated Announces Resignation Of N. Anthony Coles, M.D., As Senior Vice President, Commercial Operations
11/1/2005
-
Vertex Pharmaceuticals Incorporated Announces Webcast Of Its Presentation At The MASS Opportunities Biotechnology Investment Conference 2005
10/31/2005
-
Vertex Pharmaceuticals Incorporated Reports Third Quarter 2005 Financial Results
10/27/2005
-
The Day In Review: Biotech Higher While Market Slides
5/10/2005
-
Biotechs Drop Genomics Moniker
8/10/2004
-
Gurus Find Portfolio Cures In Biotech
6/16/2004